Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Linda Söderberg"'
Autor:
Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou, Patrik Nygren, Nicolas Fritz, Olof Zachrisson, Adeline Rachalski, Anne-Sophie Svensson, Emily Button, Giacomo Dentoni, Gunilla Osswald, Lars Lannfelt, Christer Möller
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these slow the progression of Alzheimer’s disease (AD). However, they can also cause adverse events known as amyloid-related imaging abnormalities with ed
Externí odkaz:
https://doaj.org/article/67066c16a067456492ca854e513c78f6
Autor:
Björn Johansson, Sho Oasa, Aida Muntsant Soria, Ann Tiiman, Linda Söderberg, Ebba Amandius, Christer Möller, Lars Lannfelt, Lars Terenius, Lydia Giménez-Llort, Vladana Vukojević
Publikováno v:
Cell & Bioscience, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Background Standard neuropathologic analysis of Alzheimer’s brain relies on traditional fluorescence microscopy, which suffers from limited spatial resolution due to light diffraction. As a result, it fails to reveal intricate details of a
Externí odkaz:
https://doaj.org/article/dee0db3a60734c11941bb0c8d4633267
Autor:
Fadi Rofo, Jos Buijs, Ronny Falk, Ken Honek, Lars Lannfelt, Anna M. Lilja, Nicole G. Metzendorf, Tobias Gustavsson, Dag Sehlin, Linda Söderberg, Greta Hultqvist
Publikováno v:
Translational Neurodegeneration, Vol 10, Iss 1, Pp 1-16 (2021)
Abstract Background Amyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer’s disease (AD). A number of monoclonal antibodies have entered clinical trials for AD. Some of them have failed due to the lack of
Externí odkaz:
https://doaj.org/article/e3112d378ac74be8899dc991771ba21a
Autor:
Eva Nordström, Fredrik Eriksson, Jessica Sigvardson, Malin Johannesson, Alex Kasrayan, Martina Jones-Kostalla, Paulina Appelkvist, Linda Söderberg, Patrik Nygren, Magdalena Blom, Adeline Rachalski, Karin Nordenankar, Olof Zachrisson, Ebba Amandius, Gunilla Osswald, Mikael Moge, Martin Ingelsson, Joakim Bergström, Lars Lannfelt, Christer Möller, Marco Giorgetti, Johanna Fälting
Publikováno v:
Neurobiology of Disease, Vol 161, Iss , Pp 105543- (2021)
A growing body of evidence suggests that aggregated α-synuclein, the major constituent of Lewy bodies, plays a key role in the pathogenesis of Parkinson's disease and related α-synucleinopathies. Immunotherapies, both active and passive, against α
Externí odkaz:
https://doaj.org/article/707d9ab628d84f509f885d36c2242dcb
Autor:
Stina Syvänen, Greta Hultqvist, Tobias Gustavsson, Astrid Gumucio, Hanna Laudon, Linda Söderberg, Martin Ingelsson, Lars Lannfelt, Dag Sehlin
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-10 (2018)
Abstract Background Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer’s disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance remains a challenge.
Externí odkaz:
https://doaj.org/article/f12a0b5f726a4f9cb0f180d2f407b2ee
Autor:
Sofia Söllvander, Elisabeth Nikitidou, Linn Gallasch, Marlena Zyśk, Linda Söderberg, Dag Sehlin, Lars Lannfelt, Anna Erlandsson
Publikováno v:
Journal of Neuroinflammation, Vol 15, Iss 1, Pp 1-15 (2018)
Abstract Background Currently, several amyloid beta (Aβ) antibodies, including the protofibril selective antibody BAN2401, are in clinical trials. The murine version of BAN2401, mAb158, has previously been shown to lower the levels of pathogenic Aβ
Externí odkaz:
https://doaj.org/article/9b75a98e44b64a828c1dad693d7233d2
Autor:
Anna Lord, Astrid Gumucio, Hillevi Englund, Dag Sehlin, Valentina Screpanti Sundquist, Linda Söderberg, Christer Möller, Pär Gellerfors, Lars Lannfelt, Frida Ekholm Pettersson, Lars N.G. Nilsson
Publikováno v:
Neurobiology of Disease, Vol 36, Iss 3, Pp 425-434 (2009)
Human genetics link Alzheimer's disease pathogenesis to excessive accumulation of amyloid-β (Aβ) in brain, but the symptoms do not correlate with senile plaque burden. Since soluble Aβ aggregates can cause synaptic dysfunctions and memory deficits
Externí odkaz:
https://doaj.org/article/8d9b05a83ab94d769640cf77ac14dd39
Autor:
Linda Söderberg, Dag Sehlin, Jos Buijs, Nicole G. Metzendorf, Tobias Gustavsson, Ronny Falk, Fadi Rofo, Greta Hultqvist, Anna M. Lilja, Lars Lannfelt, Ken Honek
Publikováno v:
Translational Neurodegeneration, Vol 10, Iss 1, Pp 1-16 (2021)
Translational Neurodegeneration
Translational Neurodegeneration
Background Amyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer’s disease (AD). A number of monoclonal antibodies have entered clinical trials for AD. Some of them have failed due to the lack of efficacy
Autor:
Linda Söderberg, Malin Johannesson, Patrik Nygren, Hanna Laudon, Fredrik Eriksson, Gunilla Osswald, Christer Möller, Lars Lannfelt
Publikováno v:
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of Alzheimer’s disease (AD). Aβ exists as various species, including monomers, oligomers, protofibrils, and insoluble fibrils in plaques. Oligomers and protofibrils h
Autor:
Sahar Roshanbin, Mengfei Xiong, Greta Hultqvist, Linda Söderberg, Olof Zachrisson, Silvio Meier, Sara Ekmark-Lewén, Joakim Bergström, Martin Ingelsson, Dag Sehlin, Stina Syvänen
The protein alpha-synuclein (alpha SYN) plays a central role in synucleinopathies such as Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no selective alpha SYN positron emission tomography (PET) radioligands that do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f052c566d40f81dad790a7a61d69b47f
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-473969
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-473969